Inactive

Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which... Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: May 2020: The following drug classes/subclass and agents will be reviewed: Psoriasis, SUB CLASS: N/A Sleep Disorders, SUB CLASS: Wakefulness Promoting Agents White Blood Cell, SUB CLASS: Filgrastims White Blood Cell Stimulants, SUB CLASS: Pegfilgrastims RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. The historical utilization data including quantity dispensed and 30 day equivalents by mouth is also attached herein. Pre-Proposal Teleconference: See Paragraphs 2.4 and 2.5 of the RFQ. The pre-proposal teleconference agenda with dial-in information will be sent out via email after manufacturer R.S.V.P. with the RFQ point of contact. RFQ point of contact: See Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD UPDATE as of 4/16/2020: Given the unusual circumstances COVID-19 has placed upon us all we have been forced to reschedule the Class reviews for August 2020. This update applies only to the Class Reviews and NOT the Newly Approved Drugs. Please see Amendment 0002 regarding the extension of the bid acceptance period. Please see Amendment 0003 for more updates.